Sophia Genetics (SOPH) announced a new milestone in the adoption of its cancer testing applications MSK-Access powered with Sophia DDM and MSK-Impact powered with Sophia DDM. Thirty-seven institutions have already adopted the recently launched Liquid Biopsy and Solid Tumor applications.